title: [Effectiveness, population-level effects, and heath economics of measles and rubella vaccination].
abstract: Vaccination against measles and rubella has been included in national immunization programs worldwide for several decades. In this article, we present the evidence related to the effectiveness of measles and rubella vaccination based on published systematic reviews, and we describe the epidemiological and health economic effects of vaccination at a population level. Several observational studies demonstrate the high effectiveness (> 90 %) of both measles and rubella vaccination. The global measles mortality reduction and the dramatic decrease in rubella and measles incidences after introduction of routine immunization contribute to the very high quality of evidence. The countries of the Americas have proved that it is feasible to eliminate measles and rubella by strengthening infant immunization through routine vaccination services and by conducting supplemental immunization activities in other childhood age groups so as to close immunity gaps. An economic evaluation of measles and rubella vaccination specifically for the healthcare system in Germany does not exist. However, we conducted a systematic review and identified 11 health-economic studies from other industrialized countries and one for a hypothetical industrialized country. Results indicate that vaccination against measles and rubella had either a cost-effective or even a cost-saving potential, which could be assumed with some limitations also for the German setting. In conclusion, there is compelling evidence that the available vaccines are very effective and that measles and rubella elimination is feasible if adequate vaccination strategies are implemented. In Germany, catch-up vaccination programs are urgently needed for children, adolescents, and young adults specifically in the western federal states.
authors.affiliation: Fachgebiet Impfprävention, Abteilung für Infektionsepidemiologie, Robert Koch-Institut, Seestr. 10, 13353, Berlin, Deutschland. WichmannO@rki.de
authors.forename: O
authors.initials: O
authors.lastname: Wichmann
authors.forename: B
authors.initials: B
authors.lastname: Ultsch
mesh_terms: D003362:Cost-Benefit Analysis / Q000191:economics / Q000706:statistics & numerical data; D005858:Germany / Q000453:epidemiology; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D032541:Mass Vaccination / Q000191:economics* / Q000706:statistics & numerical data; D008457:Measles / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D008458:Measles Vaccine / Q000191:economics / Q000627:therapeutic use; D015995:Prevalence; D018570:Risk Assessment; D012409:Rubella / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D012411:Rubella Vaccine / Q000191:economics / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D008458:Measles Vaccine; D012411:Rubella Vaccine